Feed BHVN
BH

Biohaven

BHVN · NYSE

$13.61 -2.05% (-$0.29)
1M +2.89%
Market Cap $1.92B
P/E Ratio -
Div. Yield -
ROE 1,328.94%

Bulios Fair Price

$11.36

16.5% downside

Preț actual

$13.61

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile BHVN sunt în prezent supraevaluate față de prețul lor de piață. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/B 157.31x
P/FFO N/A
P/S N/A
Growth
0 /100
Declining
Book val. growth 54.11%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor
ROE 1,328.94%
ROA 158.29%
Asset turnover 0.00x
Debt
33 /100
High
Current ratio 4.73x
Debt/Equity 24.30x
Net debt/EBITDA N/A
Stability
11 /100
Unstable
EPS volatility 60.94%
Profitable years 0
Beta 3.17x

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre BHVN
Online

Despre companie

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is a biotechnology company focused on researching, developing, and commercializing therapeutic products for the treatment of neurological and psychiatric disorders. The company aims to discover novel drug candidates and innovative therapies for patients suffering from migraine, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other neurological disorders. Biohaven is advancing and testing drugs in various stages of clinical trials and aspires to bring new therapeutic solutions to the field of neurological treatment. The company collaborates with academic and industry partners and focuses on innovation in the field of neuroscience. Biohaven Pharmaceutical Holding Company Ltd. (BHVN) shares may present an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with promising neurological treatment innovations and a strong commitment to addressing neurological disorders.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Vladimir Coric

Employees

274

Headquarters

New Haven

Evenimente viitoare

09 NOV.

Earnings

Upcoming earnings report

51d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.